Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Try for 8 000 /mo Starting dose 2.5 mg no pen needed save 20% Retatrutide 40 mg (ALLUVI) Next-generation triple agonist 40 mg pen ALLUVI Healthcare Retatrutide 40 mg by ALLUVI Healthcare injection pen with triple agonist GLP-1/GIP/glucagon
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist with a slightly different mechanism
One in five (19%) insured adults who have taken GLP-1s say they paid for the full cost themselves
Novos semaglutide, sold under the brand names Ozempic for diabetes and Wegovy for obesity, had been on the FDAs drug shortage list for over two years
Spacing injections out increases the risk of appetite returning between doses and weight regain over time
PMID: 14625346
US$ 23.25
US$ 21.18
US$ 27.75
